Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents

Axel Rainer Hanauske, C. Kent Osborne, Gary C. Chamness, Gary M. Clark, Barbara J. Forseth, Joy B. Buchok, Carlos L. Arteaga, Daniel D. Von Hoff

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Polypeptide growth factors bind to membrane receptors on human breast cancer cells and stimulate cell proliferation, suggesting that they may be important in growth regulation. Inhibition of the stimulatory effects of these factors might result in antineoplastic activity. Since cytotoxic drugs have been shown to alter cell membrane characteristics, we have examined the effects of a variety of antitumor drugs on the binding of epidermal growth factor (EGF) to the membrane receptor of human breast cancer cells. Twenty-four standard or investigational cytotoxic drugs were screened at a concentration of one-tenth the achievable peak plasma level for their ability to inhibit binding of 125I-EGF to its receptor in MCF-7 human breast cancer cells. Although at this concentration statistically significant inhibition of binding was observed with 11 drugs, the maximum inhibition observed was only 27%. Five agents, representing classes of drugs with different modes of action, were then studied in more detail. Of these, preincubation with 5-fluorouracil, 4-hydroperoxy-cyclophosphamide and doxorubicin inhibited MCF-7 colony formation in a dose-dependent manner, but these drugs had no effect on EGF-binding even at a concentration of 10 times the peak plasma level. Preincubation of cells with vinblastine and cisplatin, however, resulted in both reduced colony survival and a parallel reduction in EGF receptor binding. Membrane integrity, as measured by trypan blue exclusion, was not altered. Scatchard analysis of EGF binding demonstrated that the major effect of cisplain was a reduction in binding affinity. We conclude that cisplatin and vinblastine at high concentrations can inhibit the binding of EGF to human breast cancer cells offering an additional possible mechanism for their antiproliferative activity.

Original languageEnglish (US)
Pages (from-to)545-551
Number of pages7
JournalEuropean Journal of Cancer and Clinical Oncology
Volume23
Issue number5
DOIs
StatePublished - Jan 1 1987

Fingerprint

Epidermal Growth Factor Receptor
Epidermal Growth Factor
Antineoplastic Agents
Breast Neoplasms
Vinblastine
Pharmaceutical Preparations
Cisplatin
Membranes
Investigational Drugs
Trypan Blue
Fluorouracil
Doxorubicin
Cyclophosphamide
Intercellular Signaling Peptides and Proteins
Cell Proliferation
Cell Membrane
Peptides
Survival
Growth

ASJC Scopus subject areas

  • Oncology

Cite this

Hanauske, A. R., Kent Osborne, C., Chamness, G. C., Clark, G. M., Forseth, B. J., Buchok, J. B., ... Von Hoff, D. D. (1987). Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. European Journal of Cancer and Clinical Oncology, 23(5), 545-551. https://doi.org/10.1016/0277-5379(87)90318-X

Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. / Hanauske, Axel Rainer; Kent Osborne, C.; Chamness, Gary C.; Clark, Gary M.; Forseth, Barbara J.; Buchok, Joy B.; Arteaga, Carlos L.; Von Hoff, Daniel D.

In: European Journal of Cancer and Clinical Oncology, Vol. 23, No. 5, 01.01.1987, p. 545-551.

Research output: Contribution to journalArticle

Hanauske, AR, Kent Osborne, C, Chamness, GC, Clark, GM, Forseth, BJ, Buchok, JB, Arteaga, CL & Von Hoff, DD 1987, 'Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents', European Journal of Cancer and Clinical Oncology, vol. 23, no. 5, pp. 545-551. https://doi.org/10.1016/0277-5379(87)90318-X
Hanauske, Axel Rainer ; Kent Osborne, C. ; Chamness, Gary C. ; Clark, Gary M. ; Forseth, Barbara J. ; Buchok, Joy B. ; Arteaga, Carlos L. ; Von Hoff, Daniel D. / Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. In: European Journal of Cancer and Clinical Oncology. 1987 ; Vol. 23, No. 5. pp. 545-551.
@article{fddf7208a46b4f48ade7bf3ff6d3da78,
title = "Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents",
abstract = "Polypeptide growth factors bind to membrane receptors on human breast cancer cells and stimulate cell proliferation, suggesting that they may be important in growth regulation. Inhibition of the stimulatory effects of these factors might result in antineoplastic activity. Since cytotoxic drugs have been shown to alter cell membrane characteristics, we have examined the effects of a variety of antitumor drugs on the binding of epidermal growth factor (EGF) to the membrane receptor of human breast cancer cells. Twenty-four standard or investigational cytotoxic drugs were screened at a concentration of one-tenth the achievable peak plasma level for their ability to inhibit binding of 125I-EGF to its receptor in MCF-7 human breast cancer cells. Although at this concentration statistically significant inhibition of binding was observed with 11 drugs, the maximum inhibition observed was only 27{\%}. Five agents, representing classes of drugs with different modes of action, were then studied in more detail. Of these, preincubation with 5-fluorouracil, 4-hydroperoxy-cyclophosphamide and doxorubicin inhibited MCF-7 colony formation in a dose-dependent manner, but these drugs had no effect on EGF-binding even at a concentration of 10 times the peak plasma level. Preincubation of cells with vinblastine and cisplatin, however, resulted in both reduced colony survival and a parallel reduction in EGF receptor binding. Membrane integrity, as measured by trypan blue exclusion, was not altered. Scatchard analysis of EGF binding demonstrated that the major effect of cisplain was a reduction in binding affinity. We conclude that cisplatin and vinblastine at high concentrations can inhibit the binding of EGF to human breast cancer cells offering an additional possible mechanism for their antiproliferative activity.",
author = "Hanauske, {Axel Rainer} and {Kent Osborne}, C. and Chamness, {Gary C.} and Clark, {Gary M.} and Forseth, {Barbara J.} and Buchok, {Joy B.} and Arteaga, {Carlos L.} and {Von Hoff}, {Daniel D.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1016/0277-5379(87)90318-X",
language = "English (US)",
volume = "23",
pages = "545--551",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "5",

}

TY - JOUR

T1 - Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents

AU - Hanauske, Axel Rainer

AU - Kent Osborne, C.

AU - Chamness, Gary C.

AU - Clark, Gary M.

AU - Forseth, Barbara J.

AU - Buchok, Joy B.

AU - Arteaga, Carlos L.

AU - Von Hoff, Daniel D.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Polypeptide growth factors bind to membrane receptors on human breast cancer cells and stimulate cell proliferation, suggesting that they may be important in growth regulation. Inhibition of the stimulatory effects of these factors might result in antineoplastic activity. Since cytotoxic drugs have been shown to alter cell membrane characteristics, we have examined the effects of a variety of antitumor drugs on the binding of epidermal growth factor (EGF) to the membrane receptor of human breast cancer cells. Twenty-four standard or investigational cytotoxic drugs were screened at a concentration of one-tenth the achievable peak plasma level for their ability to inhibit binding of 125I-EGF to its receptor in MCF-7 human breast cancer cells. Although at this concentration statistically significant inhibition of binding was observed with 11 drugs, the maximum inhibition observed was only 27%. Five agents, representing classes of drugs with different modes of action, were then studied in more detail. Of these, preincubation with 5-fluorouracil, 4-hydroperoxy-cyclophosphamide and doxorubicin inhibited MCF-7 colony formation in a dose-dependent manner, but these drugs had no effect on EGF-binding even at a concentration of 10 times the peak plasma level. Preincubation of cells with vinblastine and cisplatin, however, resulted in both reduced colony survival and a parallel reduction in EGF receptor binding. Membrane integrity, as measured by trypan blue exclusion, was not altered. Scatchard analysis of EGF binding demonstrated that the major effect of cisplain was a reduction in binding affinity. We conclude that cisplatin and vinblastine at high concentrations can inhibit the binding of EGF to human breast cancer cells offering an additional possible mechanism for their antiproliferative activity.

AB - Polypeptide growth factors bind to membrane receptors on human breast cancer cells and stimulate cell proliferation, suggesting that they may be important in growth regulation. Inhibition of the stimulatory effects of these factors might result in antineoplastic activity. Since cytotoxic drugs have been shown to alter cell membrane characteristics, we have examined the effects of a variety of antitumor drugs on the binding of epidermal growth factor (EGF) to the membrane receptor of human breast cancer cells. Twenty-four standard or investigational cytotoxic drugs were screened at a concentration of one-tenth the achievable peak plasma level for their ability to inhibit binding of 125I-EGF to its receptor in MCF-7 human breast cancer cells. Although at this concentration statistically significant inhibition of binding was observed with 11 drugs, the maximum inhibition observed was only 27%. Five agents, representing classes of drugs with different modes of action, were then studied in more detail. Of these, preincubation with 5-fluorouracil, 4-hydroperoxy-cyclophosphamide and doxorubicin inhibited MCF-7 colony formation in a dose-dependent manner, but these drugs had no effect on EGF-binding even at a concentration of 10 times the peak plasma level. Preincubation of cells with vinblastine and cisplatin, however, resulted in both reduced colony survival and a parallel reduction in EGF receptor binding. Membrane integrity, as measured by trypan blue exclusion, was not altered. Scatchard analysis of EGF binding demonstrated that the major effect of cisplain was a reduction in binding affinity. We conclude that cisplatin and vinblastine at high concentrations can inhibit the binding of EGF to human breast cancer cells offering an additional possible mechanism for their antiproliferative activity.

UR - http://www.scopus.com/inward/record.url?scp=0023115913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023115913&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(87)90318-X

DO - 10.1016/0277-5379(87)90318-X

M3 - Article

VL - 23

SP - 545

EP - 551

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 5

ER -